Moreover, a recently published study by Shahbazi et al. [28] found a significant difference in IGF-1 expression between MS patients and the healthy controls, possibly due to gene polymorphisms differences, as patients carrying the genotype T/T showed higher serum levels of IGF-1 than other individuals carrying C/Tor C/C genotypes; however, based on previous [14, 15, 18] findings, there was no significant difference in CSF or serum IGF-1 levels between MS patients and healthy controls. This evidence concerns the gene IGF1 and myeloid sarcoma.